TY - JOUR
T1 - Discovery of robust and highly specific microbiome signatures of non-alcoholic fatty liver disease
AU - Nychas, Emmanouil
AU - Marfil-Sánchez, Andrea
AU - Chen, Xiuqiang
AU - Mirhakkak, Mohammad
AU - Li, Huating
AU - Jia, Weiping
AU - Xu, Aimin
AU - Nielsen, Henrik Bjørn
AU - Nieuwdorp, Max
AU - Loomba, Rohit
AU - Ni, Yueqiong
AU - Panagiotou, Gianni
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Background: The pathogenesis of non-alcoholic fatty liver disease (NAFLD) with a global prevalence of 30% is multifactorial and the involvement of gut bacteria has been recently proposed. However, finding robust bacterial signatures of NAFLD has been a great challenge, mainly due to its co-occurrence with other metabolic diseases. Results: Here, we collected public metagenomic data and integrated the taxonomy profiles with in silico generated community metabolic outputs, and detailed clinical data, of 1206 Chinese subjects w/wo metabolic diseases, including NAFLD (obese and lean), obesity, T2D, hypertension, and atherosclerosis. We identified highly specific microbiome signatures through building accurate machine learning models (accuracy = 0.845–0.917) for NAFLD with high portability (generalizable) and low prediction rate (specific) when applied to other metabolic diseases, as well as through a community approach involving differential co-abundance ecological networks. Moreover, using these signatures coupled with further mediation analysis and metabolic dependency modeling, we propose synergistic defined microbial consortia associated with NAFLD phenotype in overweight and lean individuals, respectively. Conclusion: Our study reveals robust and highly specific NAFLD signatures and offers a more realistic microbiome-therapeutics approach over individual species for this complex disease.
AB - Background: The pathogenesis of non-alcoholic fatty liver disease (NAFLD) with a global prevalence of 30% is multifactorial and the involvement of gut bacteria has been recently proposed. However, finding robust bacterial signatures of NAFLD has been a great challenge, mainly due to its co-occurrence with other metabolic diseases. Results: Here, we collected public metagenomic data and integrated the taxonomy profiles with in silico generated community metabolic outputs, and detailed clinical data, of 1206 Chinese subjects w/wo metabolic diseases, including NAFLD (obese and lean), obesity, T2D, hypertension, and atherosclerosis. We identified highly specific microbiome signatures through building accurate machine learning models (accuracy = 0.845–0.917) for NAFLD with high portability (generalizable) and low prediction rate (specific) when applied to other metabolic diseases, as well as through a community approach involving differential co-abundance ecological networks. Moreover, using these signatures coupled with further mediation analysis and metabolic dependency modeling, we propose synergistic defined microbial consortia associated with NAFLD phenotype in overweight and lean individuals, respectively. Conclusion: Our study reveals robust and highly specific NAFLD signatures and offers a more realistic microbiome-therapeutics approach over individual species for this complex disease.
KW - Gut microbiota
KW - Machine learning
KW - Metabolic diseases
KW - Metabolomics
KW - Microbial consortia
KW - NAFLD
KW - Network analysis
UR - https://www.scopus.com/pages/publications/85215759486
U2 - 10.1186/s40168-024-01990-y
DO - 10.1186/s40168-024-01990-y
M3 - Article
C2 - 39810263
SN - 2049-2618
VL - 13
SP - 10
JO - Microbiome
JF - Microbiome
IS - 1
M1 - 10
ER -